Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

141. A Case Report of Chikungunya Fever, Rheumatoid Arthritis, and Felty’s Syndrome (Full text)

A Case Report of Chikungunya Fever, Rheumatoid Arthritis, and Felty’s Syndrome Chronic chikungunya (CHIK) arthritis, an inflammatory arthritis, often follows acute CHIK fever (CHIKF), a viral infection. The pathogenesis of chronic CHIK arthritis is poorly characterized, but may resemble other forms of inflammatory arthritis. Clinically, chronic CHIK arthritis sometimes mimics rheumatoid arthritis (RA).We report a patient with well-characterized CHIKF followed 2 months later by chronic CHIK (...) arthritis not only resembling RA clinically, but also associated with RA biomarkers and extra-articular features, including Felty's syndrome (FS).We describe this patient's excellent response to methotrexate and discuss the implications her case provides in understanding this important emerging rheumatic disease.

2018 Rheumatology and therapy PubMed

142. Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan (Full text)

Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan Golimumab has been proven as an effective treatment for rheumatoid arthritis in clinical trials. However, there is a scarcity of data regarding its use in elderly patients in a real-world setting. This study aims to evaluate the safety, effectiveness, and treatment persistence of golimumab in elderly Japanese patients (≥ 75 years) with rheumatoid (...) arthritis.This study was a post hoc analysis of post-marketing surveillance data on 5137 Japanese patients with active rheumatoid arthritis who received golimumab for 24 weeks. The study population was divided into two age groups (younger: < 75 years and elderly: ≥ 75 years), and the safety, effectiveness, and treatment persistence of golimumab were assessed. Also, the reasons for discontinuing golimumab treatment were analyzed by multi-logistic regression.During golimumab treatment over 24 weeks, younger

2018 Rheumatology and therapy PubMed

143. Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial (Full text)

Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial To test the effect of patient-reported outcome (PRO)-based tele-health followup for tight control of disease activity in patients with rheumatoid arthritis (RA), and the differences between tele-health followup performed by rheumatologists or rheumatology nurses.A total of 294 patients were randomized (1:1:1) to either PRO-based tele-health followup carried out

2018 EvidenceUpdates PubMed

144. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis (Full text)

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis To assess the feasibility and efficacy of implementing a treat-to-target approach versus usual care in a US-based cohort of rheumatoid arthritis patients.In this behavioral intervention trial, rheumatology practices were cluster-randomized to provide treat-to-target care or usual care. Eligible patients with moderate/high disease activity (Clinical (...) . Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

2018 EvidenceUpdates PubMed

145. Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis

Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis Oral glucocorticoid (OGC) use for rheumatoid arthritis (RA) is debated because of the adverse event (AE) profile of OGC. We evaluated the associations between cumulative doses of OGC and potential OGC-related AE, and quantified the associated healthcare expenditures.Using the MarketScan databases, patients ≥ 18 years old who have RA

2018 EvidenceUpdates

146. Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis (Full text)

Maintenance of Remission with Etanercept–DMARD Combination Therapy Compared with DMARDs Alone in African and Middle Eastern Patients with Active Rheumatoid Arthritis To compare etanercept (ETN) and placebo (PBO) for maintaining low disease activity (LDA) achieved with ETN in patients with rheumatoid arthritis (RA) from Africa and the Middle East.In this subset analysis of the Treat-to-Target trial (ClinicalTrials.gov identifier NCT01981473), 53 adult patients with moderate-to-severe RA

2018 Rheumatology and therapy PubMed

147. Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients (Full text)

Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients The aim of this study was to investigate real-world treatment patterns for use of golimumab and concomitant medications in Japanese patients with rheumatoid arthritis.This study was a post hoc retrospective analysis from post-marketing surveillance data on 2350 Japanese patients with moderate/severe rheumatoid arthritis who received golimumab for 24 weeks. The study population

2018 Rheumatology and therapy PubMed

148. Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data (Full text)

Cost of Depression in Japanese Patients with Rheumatoid Arthritis: Evidence from Administrative Data To determine the cost of depression comorbidity among Japanese adults with rheumatoid arthritis (RA).A retrospective database study of 8968 patients diagnosed with RA between 2010 and 2015 and treated with any RA medication was conducted. Health care utilization characteristics were compared between patients with and without a comorbidity of depression. Propensity score matching was applied

2018 Rheumatology and therapy PubMed

149. Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis (Full text)

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting.Worldwide tofacitinib PMS data received in the Pfizer safety database from

2018 Rheumatology and therapy PubMed

150. Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis (Full text)

Hemophagocytic lymphohistiocytosis after certolizumab treatment in a patient with rheumatoid arthritis Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome that may be triggered by hereditary factors, autoimmune and immunologic disorders, infectious diseases, malignancies and medications. Suspicion of the disease and early treatment is of paramount importance. Since the presentation of HLH with only skin involvement is rare, early diagnosis may be difficult

2018 European journal of rheumatology PubMed

151. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis (Full text)

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy.We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between

2018 European journal of rheumatology PubMed

152. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies (Full text)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies Although synthetic and biologic disease-modifying antirheumatic drugs are available, many patients with rheumatoid arthritis have a difficult-to-control disease and need other treatment options. Repository corticotropin injection (RCI) may alleviate symptoms and exacerbations in patients with refractory disease.Nine patients with refractory rheumatoid arthritis were included in this study

2018 Open access rheumatology : research and reviews PubMed

153. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis (Full text)

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the effect of concomitant methotrexate (MTX) or glucocorticoid (GC) use on tofacitinib clinical efficacy.Data were pooled from two open-label, long-term extension studies of tofacitinib 5 or 10 mg twice daily in patients with RA

2018 Rheumatology and therapy PubMed

154. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14]

[Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36 [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoideaArthritis): addendum zum auftrag A17-14; auftrag A17-36. [Baricitinib (rheumatoid arthritis) - addendum to commission A17-14] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 531. 2017 Final publication URL Indexing

2018 Health Technology Assessment (HTA) Database.

155. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report]

[Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01 [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Leitliniensynopse für ein DMP rheumatoide arthritis: rapid report; auftrag V17-01. [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG

2018 Health Technology Assessment (HTA) Database.

156. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18]

[Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4 [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tofacitinib (rheumatoide arthritis): addendum zum auftrag A17-18; auftrag A17-4. [Tofacitinib (rheumatoid arthritis) - addendum to commission A17-18] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 545. 2017 Final publication URL Indexing Status

2018 Health Technology Assessment (HTA) Database.

157. [Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V]

[Sarilumab (rheumatoid arthritis) - benefit assessment according to õ35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39 [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sarilumab (rheumatoide arthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-39. [Sarilumab (rheumatoid arthritis) – benefit assessment according to §35a

2018 Health Technology Assessment (HTA) Database.

158. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis (Full text)

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD).Patients (n = 656) were randomized 2:1 to TCZ-SC 162 mg q2w or placebo-SC q2w plus DMARD

2018 EvidenceUpdates PubMed

159. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial

Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial To evaluate the efficacy, biological activity and safety of tregalizumab in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).321 patients were randomised (1:1:1:1) to placebo or tregalizumab 25, 100 or 200 mg once-weekly subcutaneously in addition to MTX treatment

2018 EvidenceUpdates

160. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment (Full text)

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment To investigate the relationship between baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients.The study was conducted in 152 RA patients treated with bDMARDs. The following patient's characteristics were studied: gender, age, disease duration, baseline

2018 European journal of rheumatology PubMed